Home >> ALL ISSUES >> 2017 Issues >> AMP case report: October 2017 test yourself answers

AMP case report: October 2017 test yourself answers

image_pdfCreate PDF

In the October 2017 issue was a report, “Primary pulmonary adenocarcinoma with an unusual molecular profile of the EGFR gene at initial presentation,” written by members of the Association for Molecular Pathology. Here are answers (in bold) to the three “test yourself ” questions that followed that case report.

1. Precision therapeutic agents are currently FDA approved for lung adenocarcinomas possessing certain mutations/rearrangements in which of the following genes?

a) KRAS

b) EGFR

c) ALK

d) a and b

e) b and c

2. Approximately 90 percent of EGFR mutations include:

a) L861Q and G719X

b) T790M and L858R

c) Exon 19 deletions

d) L858R and exon 19 deletions

e) S7681

3. T790M mutations of the EGFR gene:

a) are seen only after initial treatment.

b) can be treated with osimertinib.

c) have only prognostic significance.

d) may exist as a germline mutation associated with hereditary lung cancer.

e) b and d

CAP TODAY
X